Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Kodiak Sciences develops long-lasting antibody medicines for serious eye diseases, especially retinal conditions that can cause vision loss.
Kodiak Sciences is a biotech company working on medicines for diseases of the retina, the light-sensitive tissue at the back of the eye. Its main bet is a technology it calls antibody biopolymer conjugates, or ABCs. The idea is to take an antibody that blocks a disease-causing protein and attach it to a large, custom-built polymer, which is meant to keep the drug working in the eye for much longer than standard treatments.
The problem it is chasing is very real. Diseases like wet age-related macular degeneration and diabetic macular edema happen when abnormal blood vessels grow and leak in the retina, and patients need frequent injections directly into the eye to keep their vision. Those shots are a burden, so a drug that lasts longer between doses would be genuinely valuable. Kodiak's lead candidate, tarcocimab tedromer, targets the same protein as the blockbuster eye drugs sold by Regeneron and Roche, but aims to extend the time between injections.
The company does not sell anything yet. It earns no product revenue and funds its work by raising money from investors, and its stock has been volatile as key trials have disappointed and forced it to rethink parts of its pipeline. Biotech of this kind is a high-risk, high-reward game: one strong trial result can change everything, and one weak result can wipe out years of work. Kodiak is headquartered in Palo Alto, California, and its story so far is a reminder that in drug development, promising science and commercial success are two very different things.
Saved answer 路 last researched 16 Nov 2026